Lung Cancer Trials Ask AI to find trials
Active Not RecruitingNot applicableNCT02991677
Official study title

Exercise Effect on Chemotherapy-Induced Neuropathic Pain

Study summary

Chemotherapy-induced peripheral neuropathy (CIPN) continues to be a serious healthcare concern. It is painful, persistent, resistant to conventional pain therapies, and results in long-term suffering and decreased quality of life for many cancer survivors. The role of exercise to decrease CIPN-related neuropathic pain (CIPN-NP) will be investigated, with the goal of identifying the mechanisms associated with this therapeutic approach to manage CIPN-NP.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedaerobic exercise intervention and control group

Plus 1 other study approaches.

Who it may be forCancer, Breast · Cancer, Colorectal

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 6, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Baltimore VA Medical Center

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Not applicable
Sponsor
Baltimore VA Medical Center
Interventions being studied
Behavioral: aerobic exercise intervention; Other: control group; Behavioral: resistive training
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
Chemotherapy→Supportive or behavioral care→
Study topics
Survivorship and quality of life→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Diagnosis with cancer, stage I-IV
  • History of treatment with oxaliplatin, docetaxel, or paclitaxel, either alone or in combination with other agents
  • Completion of chemotherapy \> 6 months \< 1 year
  • Ability to walk on a treadmill
  • Medical clearance from oncologist or primary care provider
  • Presence of CIPN per National Cancer Institute Common Toxicity Criteria grade 1-3 (0-no signs/symptoms, 1-minor loss of function, 2-increased symptoms not interfering with activities of daily living (ADLs), 3-severe symptoms interfering with ADL, 4-disabling, and 5 is death)
  • Score on Neuropathic Pain Scale \>1
  • Age 21-70
Reasons someone may not be able to joinExclusion criteria
  • Denial of CIPN
  • Other motor/sensory neuropathy caused by other than chemotherapy (i.e.alcohol-related, autoimmune diseases, diabetes)
  • Coronary artery disease
  • History of \>1 chemotherapy regimen
  • Musculoskeletal conditions which preclude participation in an exercise training program
  • Pregnancy
  • Regular exerciser, defined as \>90 minutes per week of aerobic exercise and any resistive training

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Baltimore VA Medical CenterBaltimore, Maryland

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 6, 2024. Always confirm current availability with the study team.

View original record ↗